We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antimicrobial Peptide Attacks Pseudomonas aeruginosa

By HospiMedica staff writers
Posted on 20 Feb 2007
A new study describes how a powerful microbe fighter could be converted into a guided missile that strikes specifically at common bacteria responsible for serious infections throughout the body.

Researchers at the Israel Institute of Technology (Technion, Haifa) have found a way to activate an antimicrobial peptide--a small molecule made of short chains of amino acids--that attacks Pseudomonas aeruginosa. More...
Unlike most antibiotics, antimicrobial peptides can sidestep microbe resistance mechanisms and destroy the organism by brute force, often by simply ripping a hole in a targeted cell; the number and order of amino acids in an antimicrobial peptide determines how it recognizes and attacks an invading microbe. However, this non-specific action can also destroy normal red blood cells.

To build a more useful and less toxic antimicrobial peptide, the researchers removed a few amino acids from one end of a dermaseptin peptide--a well-known family of peptides that destroy a wide range of microbes--and replaced it with a fatty acid molecule, making the peptide deadly against P aeruginosa while leaving other bacteria alone. The new peptide is also 60 times less likely to adhere to red blood cells. The research was reported in the January 2007 issue of the journal Chemistry and Biology.

"Antimicrobial peptides present an obvious advantage over conventional antibiotics,” said Professor Amram Mor of the biotechnology and food engineering faculty. "Many experts believe that one of the factors that might hamper the commercial use of antimicrobial peptides is their prohibitive cost. Therefore, smaller means cheaper and in this case, more potent.”

Pseudomonas aeruginosa is the bacterium behind serious lung infections in people with cystic fibrosis (CF) and some types of pneumonia and meningitis, as well as less serious but widespread infections such as swimmer's ear and urinary tract infections.




Related Links:
Israel Institute of Technology

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.